1169 / 1578
/
Overview
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
35
1.
General outline
2.
SBRT combined with targeted drugs
3.
SBRT combined with immunotherapy
4.
Safety of SBRT combined with novel drugs
/
Use of concurrent SRT and novel drugs
in the DEGRO society
Ø
Concurrent treatment with SRT and targeted drugs
performed by many institutions, already
Targeted therapy
Targeted therapy simultan zur SBRT
n (%)
Antikörper
Bevacizumab
0
Ipilimumab
8 (30%)
Cetuximab
7 (26%)
Panitumumab
5 (19%)
Trastuzumab
14 (52%)
Nivolumab
7 (26%)
Pembrolizumab
7 (26%)
Tyrosine Kinase Inhibitoren
Vemurafenib
2 (7%)
Sorafenib
4 (15%)
Erlotinib
7 (26%)
Lapatinib
6 (22%)
Gefitinib
5 (19%)
Crizotinib
5 (19%)
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
36